肿瘤异质性与组织采样对基因突变检测的影响:系统综述与事后分析
对12个前列腺肿瘤体细胞突变数据集的事后分析显示,报告病理方法和肿瘤纯度的比例有限。
要点
- 未发现正式指南指导系统评价者识别肿瘤异质性所致采样偏倚。
- 零散建议集中在多样本采样、样本纯度阈值和特定测序方法等五个主题。
核心结论
- 随着精准医学进入临床,需要指南帮助循证决策者理解肿瘤异质性对样本偏倚的影响。
- 作者应清晰报告病理方法和结果以及肿瘤纯度方法和结果。
研究设计与样本
- 系统综述检索13个数据库(截至2019年1月)以识别指南。
- 事后分析使用来自既往系统综述的12个前列腺肿瘤体细胞突变数据集评估肿瘤异质性报告情况。
主要发现
- 检索识别2085条记录,未发现正式指南。
关键数值与推荐
- 零散建议主题包括使用多个肿瘤样本(n=29)、样本纯度阈值(n=14)、使用特定测序方法(n=8)、使用液体活检(n=4)和显微切割(n=4)。
- 事后分析中肿瘤纯度报告范围为10%至100%。
临床怎么用
- 系统评价者或临床研究者在评估实体癌体细胞突变检测时,应关注肿瘤异质性所致采样偏倚。
- 研究作者应清晰报告病理方法、病理结果、肿瘤纯度方法和结果。
局限性
- 未发现正式指南,仅基于零散建议。
- 事后分析仅使用12个前列腺肿瘤数据集,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to identify guidelines to assist systematic reviewers or clinical researchers in identifying sampling bias due to tumor heterogeneity (TH) in solid cancers assayed for somatic mutations. We also assessed current reporting standards to determine the impact of TH on sample bias. STUDY DESIGN AND SETTING: We conducted a systematic review searching 13 databases (to January 2019) to identify guidelines. A post hoc analysis was performed using 12 prostate tumor somatic mutation data sets from a previous systematic review to assess reporting on TH. RESULTS: Searches identified 2,085 records. No formal guidelines were identified. Forty publications contained incidental recommendations across five major themes: using multiple tumor samples (n = 29), sample purity thresholds (n = 14), using specific sequencing methods (n = 8), using liquid biopsies (n = 4), and microdissection (n = 4). In post hoc analyses, 50% (6 of 12) clearly reported pathology methods. Forty-two percent (5 of 12) did not report pathology results. Forty-two percent (5 of 12) confirmed the pathology of the sample by direct diagnosis rather than inference. Forty-two percent (5 of 12) used multiple samples per patient. Fifty-eight percent (7 of 12) reported on tumor purity (reported ranges 10% to 100%). CONCLUSIONS: As precision medicine progresses to the clinic, guidelines are required to help evidence-based decision makers understand how TH may impact sample bias. Authors need to clearly report pathology methods and results and tumor purity methods and results.
引用
- Swift SL, Duffy S, Lang SH, et al. Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis. J Clin Epidemiol. 2020. PMID: 32540382. doi:10.1016/j.jclinepi.2020.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。